CDA-AMC’s recent enhancements to the reimbursement review process are reshaping the Canadian HTA landscape. With the first draft recommendations issued under the new framework in late 2025, clear themes are emerging that will influence how Sponsors prepare submissions in the year ahead.
In this POV, Christine Malmberg, Sumeet Singh, and Kamalpreet Mann examine what these changes mean in practice, including the growing importance of Evidence Presentation Meetings, new opportunities for Sponsors to propose clinical experts and recommendation criteria, and the increasing role of social and ethical considerations in reimbursement decisions.
Together, these insights offer practical guidance for navigating an evolving HTA environment and strengthening future submissions.
To explore these insights and learn how Sponsors can prepare stronger, more strategic submissions in an evolving HTA environment, you can access the full article here.
Author
Christine is a former hospital-based clinician who has worked as a market access consultant to the Canadian pharma industry for over 15 years. She has substantial knowledge of the Canadian reimbursement environment, having gained…
Senior Director of Market Access and Pricing, Kamal is a highly proficient professional with a wide range of experience in the pharmaceutical industry and consulting. In her past roles, Kamal was part of the…
Sumeet Singh is Vice President, HEOR at EVERSANA where he leads HEOR projects for Canadian and global pharmaceutical clients. Prior to joining EVERSANA, Sumeet held various leadership positions at Canada’s Drug Agency (formerly CADTH).…